A Novel Color Change Mechanism for Breast Cancer Biomarker Detection: Naphthoquinones as Specific Ligands of Human Arylamine N-Acetyltransferase 1

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Laurieri, Nicola ^a   Egleton, James E ^a   Varney, Amy ^a   Thinnes, Cyrille C ^a   Quevedo, Camilo E ^a   Seden, Peter T ^a   Thompson, Sam ^a   Rodrigues Lima, Fernando ^b   Dairou, Julien ^b   Dupret, Jean Marie ^b   Russell, Angela J ^a   Sim, Edith ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Groupe Hospitalier Pitié Salpêtrière   (France)

^c KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; HUMAN ARYLAMINE N ACETYLTRANSFERASE 1; ISOENZYME; LIGAND; MURINE ARYLAMINE N ACETYLTRANSFERASE 2; NAPHTHOQUINONE; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; COLORIMETRY; CONJUGATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISEASE MARKER; ENZYME ACTIVE SITE; ENZYME SUBSTRATE COMPLEX; ENZYMIC BIOSENSOR; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; MOLECULAR DOCKING; MOLECULAR MODEL; NITROGEN NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; BREAST NEOPLASMS; CATALYTIC DOMAIN; COLOR; FEMALE; HUMANS; ISOENZYMES; MICE; NAPHTHOQUINONES; PROTEIN BINDING; TUMOR MARKERS, BIOLOGICAL;

EID: 84881095929     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070600     Document Type: Article

References (29)

1. Ransohoff DF, (2003) Cancer. Developing molecular biomarkers for cancer. Science 299: 1679-1680.
2. Dalton WS, Friend SH, (2006) Cancer biomarkers-an invitation to the table. Science 312: 1165-1168.
3. Kelloff GJ, Sigman CC, (2012) Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 11: 201-214.
4. Wang BQ, Xia CH, Lv Y, Gao GG, Wu H, (2011) Inorganic nanomaterial applications in cancer detection. Materials Technol 26: 236-242.
5. Nomura DK, Dix MM, Cravatt BF, (2010) Activity-based protein profiling for biochemical pathway discovery in cancer. Nature Rev Cancer 10: 630-638.
6. Soh N, (2008) Selective chemical labeling of proteins with small fluorescent molecules based on metal-chelation methodology. Sensors 8: 1004-1024.
7. Li N, Overkleeft HS, Florea BI, (2012) Activity-based protein profiling: an enabling technology in chemical biology research. Curr Opin Chem Biol 16: 227-233.
8. Adam PJ, Berry J, Loader JA, Tyson KL, Craggs G, et al. (2003) Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res 1: 826-835.
9. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, et al. (2006) Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 13: 1109-1120.
10. Wakefield L, Robinson J, Long H, Ibbitt JC, Cooke S, et al. (2008) Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors. Genes Chromosomes Cancer 47: 118-126.
11. Johansson I, Nilsson C, Berglund P, Lauss M, Ringner M, et al. (2012) Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res 14: R31.
12. Bieche I, Girault I, Urbain E, Tozlu S, Lidereau R, (2004) Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res 6: R252-263.
13. Sim E, Fakis G, Laurieri N, Boukouvala S, (2012) Arylamine N-acetyltransferases-from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention. Adv Pharmacol 63: 169-205.
14. Westwood IM, Kawamura A, Russell AJ, Sandy J, Davies SG, et al. (2011) Novel small-molecule inhibitors of arylamine N-acetyltransferases: drug discovery by high-throughput screening. Comb Chem High Throughput Screen 14: 117-124.
15. Russell AJ, Westwood IM, Crawford MH, Robinson J, Kawamura A, et al. (2009) Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2. Bioorg Med Chem 17: 905-918.
16. Laurieri N, Crawford MH, Kawamura A, Westwood IM, Robinson J, et al. (2010) Small molecule colorimetric probes for specific detection of human arylamine N-acetyltransferase 1, a potential breast cancer biomarker. J Am Chem Soc 132: 3238-3239.
17. Kawamura A, Westwood I, Wakefield L, Long H, Zhang N, et al. (2008) Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1. Biochem Pharmacol 75: 1550-1560.
18. Wu H, Dombrovsky L, Tempel W, Martin F, Loppnau P, et al. (2007) Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. J Biol Chem 282: 30189-30197.
19. Goodfellow GH, Dupret JM, Grant DM, (2000) Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem J 348 Pt 1: 159-166.
20. Westwood IM, Kawamura A, Fullam E, Russell AJ, Davies SG, et al. (2006) Structure and mechanism of arylamine N-acetyltransferases. Curr Top Med Chem 6: 1641-54.
21. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular Cloning. A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
22. Dairou J, Atmane N, Dupret JM, Rodrigues-Lima F, (2003) Reversible inhibition of the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 by S-nitrosothiols. Biochem Biophys Res Commun 307: 1059-1065.
23. Brooke EW, Davies SG, Mulvaney AW, Pompeo F, Sim E, et al. (2003) An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases. Bioorg Med Chem 11: 1227-1234.
24. Wang H, Vath GM, Gleason KJ, Hanna PE, Wagner CR, (2004) Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification, site-directed mutagenesis, and pre-steady state and steady state kinetic studies. Biochemistry 43: 8234-8246.
25. Wang H, Guo Z, Vath GM, Wagner CR, Hanna PE, (2004) Chemical modification of hamster arylamine N-acetyltransferase 2 with isozyme-selective and nonselective N-arylbromoacetamido reagents. Protein J 23: 153-166.
26. Arnold K, Bordoli L, Kopp J, Schwede T, (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2: 195-201.
27. Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T, (2009) The SWISS-MODEL Repository and associated resources. Nucleic Acids Res 37: D387-92.
28. Peitsch MC, (1995) Protein Modeling by E-Mail. Bio-Technology 13: 658-660.
29. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD, (2003) Improved protein-ligand docking using GOLD. Proteins-Structure Function and Genetics 52: 609-623.